PL2164866T3 - Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek - Google Patents

Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek

Info

Publication number
PL2164866T3
PL2164866T3 PL08757166T PL08757166T PL2164866T3 PL 2164866 T3 PL2164866 T3 PL 2164866T3 PL 08757166 T PL08757166 T PL 08757166T PL 08757166 T PL08757166 T PL 08757166T PL 2164866 T3 PL2164866 T3 PL 2164866T3
Authority
PL
Poland
Prior art keywords
aprotinin
polypeptides
tissues
delivering agents
agents conjugated
Prior art date
Application number
PL08757166T
Other languages
English (en)
Inventor
Richard Beliveau
Michel Demeule
Christian Che
Anthony Regina
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/807,597 external-priority patent/US20090016959A1/en
Priority claimed from US11/807,917 external-priority patent/US8969310B2/en
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of PL2164866T3 publication Critical patent/PL2164866T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL08757166T 2007-05-29 2008-05-29 Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek PL2164866T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/807,597 US20090016959A1 (en) 2005-02-18 2007-05-29 Delivery of antibodies to the central nervous system
US11/807,917 US8969310B2 (en) 2005-07-15 2007-05-30 Potentiation of anticancer agents
US888007P 2007-12-20 2007-12-20
EP08757166.7A EP2164866B1 (en) 2007-05-29 2008-05-29 Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PCT/CA2008/001030 WO2008144919A1 (en) 2007-05-29 2008-05-29 Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues

Publications (1)

Publication Number Publication Date
PL2164866T3 true PL2164866T3 (pl) 2014-10-31

Family

ID=40074513

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08757166T PL2164866T3 (pl) 2007-05-29 2008-05-29 Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek

Country Status (6)

Country Link
EP (2) EP2789628A3 (pl)
CN (1) CN101815724B (pl)
AU (1) AU2008255556B2 (pl)
CA (1) CA2688344C (pl)
PL (1) PL2164866T3 (pl)
WO (1) WO2008144919A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2709635A1 (en) * 2007-12-20 2009-07-02 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
JP5860698B2 (ja) * 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
EP2346906A4 (en) * 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5759379B2 (ja) * 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US20110288009A1 (en) * 2008-12-05 2011-11-24 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
WO2010069074A1 (en) * 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
DE102009006228A1 (de) 2009-01-27 2010-07-29 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
KR101043407B1 (ko) * 2009-02-19 2011-06-22 한국과학기술연구원 암 표적성이 우수한 단백질 복합체 및 이의 제조방법
EP2421562B1 (en) * 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20120196803A1 (en) * 2009-06-11 2012-08-02 Angiochem Inc. Fusion proteins for delivery of gdnf and bdnf to the central nervous system
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
CA2807554C (en) 2010-08-05 2021-10-26 Forsight Vision4 Inc. Implantable therapeutic device
WO2012037687A1 (en) * 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP4249059B1 (en) 2011-06-28 2025-07-30 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP4643921A3 (en) 2011-09-16 2026-01-07 ForSight Vision4, Inc. Fluid exchange apparatus
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
CN109354623B (zh) * 2012-04-25 2022-06-24 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
AU2013302273A1 (en) * 2012-08-14 2015-02-19 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
MX377795B (es) * 2012-11-12 2025-03-11 Angiochem Inc Conjugados de polipeptido derivado de aprotinina-anticuerpo.
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2014160884A1 (en) 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
CN103948598B (zh) * 2014-04-15 2016-09-28 上海交通大学医学院 治疗慢性粒细胞白血病的联合用药物
ES2992100T3 (es) 2014-07-15 2024-12-09 Forsight Vision4 Inc Dispositivo de administración de implante ocular
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.
SG11201703726XA (en) 2014-11-10 2017-06-29 Forsight Vision4 Inc Expandable drug delivery devices and method of use
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
CN113069681B (zh) 2015-11-20 2022-12-23 弗赛特影像4股份有限公司 制造用于缓释药物递送的治疗装置的方法
CN109195556B (zh) 2016-04-05 2021-03-26 弗赛特影像4股份有限公司 可植入眼睛药物递送装置
BR112020010053A2 (pt) 2017-11-21 2020-11-03 Forsight Vision4, Inc. aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo
CN112569359A (zh) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
WO1994007528A1 (en) 1992-09-25 1994-04-14 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia-tissue factor complex
MX9307777A (es) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2368941T3 (es) * 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych

Also Published As

Publication number Publication date
EP2164866B1 (en) 2014-05-14
AU2008255556B2 (en) 2014-08-07
EP2789628A3 (en) 2015-03-04
AU2008255556A1 (en) 2008-12-04
CA2688344A1 (en) 2008-12-04
CN101815724A (zh) 2010-08-25
CA2688344C (en) 2019-09-03
EP2164866A1 (en) 2010-03-24
CN101815724B (zh) 2015-02-25
WO2008144919A1 (en) 2008-12-04
EP2164866A4 (en) 2010-06-09
EP2789628A2 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
PL2164866T3 (pl) Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
GB0811304D0 (en) Therapeutic agents
ZA200906525B (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
GB0819593D0 (en) Therapeutic agents
GB0723747D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0801081D0 (en) Therapeutic agents
IL197235A0 (en) Therapeutic compositions
GB0801080D0 (en) Therapeutic agents
GB0808835D0 (en) Therapeutic compositions
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0724340D0 (en) Novel Therapeutic Agents
GB0819958D0 (en) Therapeutic compositions
PL2424870T3 (pl) Środki terapeutyczne 713
PT2164866E (pt) Polipéptidos de tipo aprotinina para administrar agentes conjugados com os mesmos aos tecidos
SI2164866T1 (sl) Aprotininu podobni polipeptidi za dostavljanje sredstev, ki so na njih konjugirana tkivom
GB0723748D0 (en) Therapeutic agents
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0811715D0 (en) Therapeutic agents
GB0723751D0 (en) Therapeutic agents
GB0723749D0 (en) Therapeutic agents
GB0725030D0 (en) Therapeutic agents